AU2012220314B2 - Cystamine analogues for the treatment of Parkinson's disease - Google Patents

Cystamine analogues for the treatment of Parkinson's disease Download PDF

Info

Publication number
AU2012220314B2
AU2012220314B2 AU2012220314A AU2012220314A AU2012220314B2 AU 2012220314 B2 AU2012220314 B2 AU 2012220314B2 AU 2012220314 A AU2012220314 A AU 2012220314A AU 2012220314 A AU2012220314 A AU 2012220314A AU 2012220314 B2 AU2012220314 B2 AU 2012220314B2
Authority
AU
Australia
Prior art keywords
cystamine
parkinson
disease
pharmaceutically acceptable
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012220314A
Other languages
English (en)
Other versions
AU2012220314A1 (en
Inventor
Frederic Calon
Francesca Cicchetti
Claude Rouillard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Université Laval
Original Assignee
Université Laval
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Université Laval filed Critical Université Laval
Publication of AU2012220314A1 publication Critical patent/AU2012220314A1/en
Application granted granted Critical
Publication of AU2012220314B2 publication Critical patent/AU2012220314B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2012220314A 2011-02-23 2012-02-23 Cystamine analogues for the treatment of Parkinson's disease Ceased AU2012220314B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161445577P 2011-02-23 2011-02-23
CA2732440A CA2732440C (en) 2011-02-23 2011-02-23 Cystamine analogues for the treatment of parkinson`s disease
US61/445,577 2011-02-23
CA2,732,440 2011-02-23
PCT/CA2012/050106 WO2012113079A1 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
AU2012220314A1 AU2012220314A1 (en) 2013-08-22
AU2012220314B2 true AU2012220314B2 (en) 2017-04-06

Family

ID=46717621

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012220314A Ceased AU2012220314B2 (en) 2011-02-23 2012-02-23 Cystamine analogues for the treatment of Parkinson's disease

Country Status (11)

Country Link
US (1) US20140073694A1 (enExample)
EP (1) EP2678009B1 (enExample)
JP (1) JP6000985B2 (enExample)
KR (1) KR20140115239A (enExample)
CN (1) CN103442704A (enExample)
AU (1) AU2012220314B2 (enExample)
BR (1) BR112013021616A2 (enExample)
CA (1) CA2732440C (enExample)
MX (1) MX350195B (enExample)
RU (1) RU2630583C2 (enExample)
WO (1) WO2012113079A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI659209B (zh) * 2013-06-17 2019-05-11 地平線罕見醫學製藥有限責任公司 分析半胱胺組合物的方法
TW201618760A (zh) * 2014-11-05 2016-06-01 雷普特製藥有限公司 使用半胱胺組合物治療亨廷頓氏病之方法
CN113197851A (zh) 2015-05-06 2021-08-03 辛纳吉勒公司 包含药物粒子的药用悬浮液、用于其配给的装置、以及其使用方法
RU2766579C2 (ru) 2015-07-02 2022-03-15 ХОРАЙЗОН ОРФАН ЭлЭлСи Цистеаминдиоксигеназа-резистентные аналоги цистеамина и их применение
WO2017166139A1 (zh) 2016-03-30 2017-10-05 广东欧珀移动通信有限公司 中继传输的方法和装置
WO2020198529A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Ofcalifornia Substituted amino-thiol and amino-disulfide compounds, and uses thereof
WO2021022012A1 (en) * 2019-07-30 2021-02-04 The Regents Of The University Of California Methods and composition for treating respiratory obstructive diseases
CN119909064B (zh) * 2025-04-07 2025-08-15 北京大学深圳研究生院 胱胺衍生物或其盐以及其在制备具有抗氧化功效的药物中的应用
CN120437102B (zh) * 2025-07-09 2025-09-16 中南大学湘雅医院 胱胺在制备治疗脓毒症脑病药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060211624A1 (en) * 2003-02-02 2006-09-21 Goverment of the US, as Represented by Methods and compositions for the treatment of parkinson's disease and other alpha-synucleinopathies
RU2255775C1 (ru) * 2003-12-25 2005-07-10 Государственное учреждение научно-исследовательский институт неврологии Российской академии медицинских наук Способ лечения болезни паркинсона
WO2007089670A2 (en) * 2006-01-27 2007-08-09 The Regents Of The University Of California Enterically coated cysteamine, cystamine and derivatives thereof
WO2008143876A2 (en) * 2007-05-14 2008-11-27 The Trustees Of Columia University In The City Of New York Agents and assays for modulating neurodegeneration
EP2296462A4 (en) * 2008-06-13 2011-06-15 Teva Pharma RASAGILINE FOR INFLUENCING MORBUS PARKINSON

Also Published As

Publication number Publication date
BR112013021616A2 (pt) 2020-09-29
US20140073694A1 (en) 2014-03-13
MX350195B (es) 2017-08-30
AU2012220314A1 (en) 2013-08-22
EP2678009A1 (en) 2014-01-01
JP2014508758A (ja) 2014-04-10
RU2013137645A (ru) 2015-02-20
KR20140115239A (ko) 2014-09-30
MX2013009608A (es) 2013-09-16
WO2012113079A1 (en) 2012-08-30
EP2678009A4 (en) 2014-08-06
CN103442704A (zh) 2013-12-11
CA2732440A1 (en) 2012-08-23
EP2678009B1 (en) 2017-11-01
CA2732440C (en) 2017-10-31
RU2630583C2 (ru) 2017-09-11
JP6000985B2 (ja) 2016-10-05

Similar Documents

Publication Publication Date Title
EP2678009B1 (en) Cystamine analogues for the treatment of parkinson&#39;s disease
JP6608309B2 (ja) Ｃｍｔ及び関連疾患の処置のための新規な治療的アプローチ
Zheng et al. Icariin targets Nrf2 signaling to inhibit microglia-mediated neuroinflammation
Onaolapo et al. Peripheral and central glutamate dyshomeostasis in neurodegenerative disorders
TW201216958A (en) Synthetic triterpenoids and methods of use in the treatment of disease
EP2931273A1 (en) Methods of treating portal hypertension
US20190046471A1 (en) Methods and Compositions for the Treatment of Steatosis-Associated Disorders
JP7385924B2 (ja) エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物
Esposito et al. Death in the substantia nigra: a motor tragedy
CN103189056A (zh) L-dopa、多巴胺激动剂和/或多巴胺增强剂诱导的紊乱的治疗
Negida et al. Caffeine; the forgotten potential for Parkinson's disease
JP2014513065A (ja) （３ａＲ）−１，３ａ，８−トリメチル−１，２，３，３ａ，８，８ａ−ヘキサヒドロピロロ［２，３−ｂ］インドール−５−イルフェニルカルバメートの有効量およびその使用方法
Sun et al. SIRT1 activation attenuates microglia-mediated synaptic engulfment in postoperative cognitive dysfunction
Wang et al. Phytic acid attenuates upregulation of GSK-3β and disturbance of synaptic vesicle recycling in MPTP-induced Parkinson's disease models
Gibrat et al. Cystamine prevents MPTP-induced toxicity in young adult mice via the up-regulation of the brain-derived neurotrophic factor
CN101316584A (zh) 用于预防及治疗由血管通透性亢进引起的眼病的医药
C Brett et al. Current therapeutic advances in patients and experimental models of Huntington's disease
Tulimiero et al. Diaphragm‐specific effects of L‐citrulline in mdx mice highlight its potential as adjuvant of standard therapy in Duchenne muscular dystrophy
Thapliyal et al. Novel Metabolic Biomarkers and Therapeutic Strategies in Neurodegenerative Diseases
Dhir et al. Nitric oxide (NO) system in major depression: studies on NO synthase inhibitors as antidepressant agents
Natalia et al. Alterations of Lipid-Mediated Mitophagy Result in Aging-Dependent Sensorimotor Defects
WO2025197131A1 (ja) 非ヒト哺乳動物のがんの治療剤
WO2023212795A1 (en) Use of glycine transporter- 1 antagonists as vascular dementia and/or stroke prophylactic/treatment agents
WO2024040256A2 (en) Pharmaceutical combinations and methods for preventing or treating neurodegenerative diseases
Henchcliffe et al. Potential therapies for mitochondrial dysfunction

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired